

Chief Science Officer Richard Amadio and Executive Vice President of R&D

LOS ANGELES, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) — Celson Corporation (NASDAQ: CLON) is pleased to announce its participation in the Cytokine-Based Cancer Immunotherapy Summit being held in Boston on November 10 and November 11, 2021. Dr. Amadio will also be participating in two panel discussions on the importance of safety and efficacy in the design of cytokine-based cancer immunotherapy. Dr. Amadio will also be participating in a panel discussion on the importance of safety and efficacy in the design of cytokine-based cancer immunotherapy. Dr. Amadio will also be participating in a panel discussion on the importance of safety and efficacy in the design of cytokine-based cancer immunotherapy. Dr. Amadio will also be participating in a panel discussion on the importance of safety and efficacy in the design of cytokine-based cancer immunotherapy. Dr. Amadio will also be participating in a panel discussion on the importance of safety and efficacy in the design of cytokine-based cancer immunotherapy.

About Celson Corporation

Celson Corporation is a biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company's pipeline includes GEN-1, a first-in-class, IL-12-based immunotherapy for the treatment of solid tumor cancers. GEN-1 is a first-in-class, IL-12-based immunotherapy for the treatment of solid tumor cancers. GEN-1 is a first-in-class, IL-12-based immunotherapy for the treatment of solid tumor cancers. GEN-1 is a first-in-class, IL-12-based immunotherapy for the treatment of solid tumor cancers. GEN-1 is a first-in-class, IL-12-based immunotherapy for the treatment of solid tumor cancers. GEN-1 is a first-in-class, IL-12-based immunotherapy for the treatment of solid tumor cancers.

Forward Looking Statements

This press release contains certain statements that are forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. These forward-looking statements are based on the information known to the company as of the date of this press release. The company's actual performance may differ from the results indicated by these forward-looking statements. These forward-looking statements should not be relied upon as a guarantee of the company's future performance. The company's actual performance may differ from the results indicated by these forward-looking statements. These forward-looking statements should not be relied upon as a guarantee of the company's future performance. The company's actual performance may differ from the results indicated by these forward-looking statements. These forward-looking statements should not be relied upon as a guarantee of the company's future performance.